Holen Sie sich die Stockscreener-App
33.92
1.22%
0.41
Schlusskurs vom Vortag:
$33.51
Offen:
$33.5
24-Stunden-Volumen:
45,916
Relative Volume:
0.60
Marktkapitalisierung:
$1.54B
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
+11.25%
1M Leistung:
+29.47%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$29.93
$35.34
52-Wochen-Spanne:
$21.00
$37.27
Korsana Biosciences, Inc. Common Stock Stock (KRSA) Company Profile
Firmenname
Korsana Biosciences, Inc. Common Stock
Sektor
Branche
Telefon
-
Adresse
-
Compare KRSA vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRSA
Korsana Biosciences, Inc. Common Stock
|
33.92 | 1.54B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korsana Biosciences, Inc. Common Stock Stock (KRSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-05 | Eingeleitet | Wedbush | Outperform |
| 2026-09-28 | Eingeleitet | Guggenheim | Buy |
| 2026-09-14 | Eingeleitet | Stifel | Buy |
| 2026-09-14 | Eingeleitet | TD Cowen | Buy |
| 2026-09-11 | Eingeleitet | UBS | Buy |
| 2021-10-20 | Eingeleitet | Truist | Buy |
| 2021-09-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-03 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Korsana Biosciences, Inc. Common Stock Aktie (KRSA) Neueste Nachrichten
A passive stake above 5% in Korsana Biosciences (KRSA) is reported by FMR LLC in an amendment. - Stock Titan
Korsana Biosciences (NASDAQ: KRSA) director to sell 100 more shares after 2,139 sold recently - Stock Titan
After two September sales, a Korsana Biosciences (KRSA) director proposes selling 4,903 more shares. - Stock Titan
General Atlantic’s stake in Korsana (CYCN) comes with a strict ownership cap - Stock Titan
Korsana Biosciences (CYCN) director proposes $74.8K stock sale - Stock Titan
A fund reports a 6.1% passive stake in Korsana Biosciences (CYCN), with the investor's identity detailed in the filing. - Stock Titan
Nearly 10% of Korsana Biosciences (CYCN) is tied to one investor group, but its ownership is capped below that line. - Stock Titan
Diluted net income available to common stockholders of Korsana Biosciences, Inc. – NASDAQ:KRSA - TradingView
Korsana Biosciences, Inc. Statistics – NASDAQ:KRSA - TradingView
Investor gains significant stake and board power at Korsana Biosciences (CYCN) - Stock Titan
Korsana Biosciences, Inc. (KRSA) Company Information - Simply Wall Street
Why a 9.99% cap now limits a key Korsana (CYCN) holder - Stock Titan
CFO option stakes detailed at Korsana Biosciences (CYCN) after merger - Stock Titan
Merger gives Korsana Biosciences (CYCN) CMO options expiring in 2036 - Stock Titan
Korsana Biosciences (CYCN) director holds merger-issued option - Stock Titan
New Korsana Biosciences (CYCN) director reports 28,805-share option - Stock Titan
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million - The Manila Times
CYCN Stock Explodes 313% on April 1 After Cyclerion-Korsana Merger Deal for Alzheimer's Pipeline - International Business Times Australia
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement - Business Wire
Why is Biotech Stock Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) Gaining? - Investorideas.com
Cyclerion Therapeutics and Korsana Biosciences To Merge - citybiz
Cyclerion Therapeutics and Korsana Biosciences to merge - The Pharma Letter
CYCN Merges with Korsana Biosciences for Strategic Growth - GuruFocus
Finanzdaten der Korsana Biosciences, Inc. Common Stock-Aktie (KRSA)
Es liegen keine Finanzdaten für Korsana Biosciences, Inc. Common Stock (KRSA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Korsana Biosciences, Inc. Common Stock-Aktie (KRSA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ERROL B DE SOUZA | Director |
Sep 22 '26 |
Proposed Sale |
34.99 |
100 |
3,499 |
0 |
| ERROL B DE SOUZA | Director |
Sep 18 '26 |
Proposed Sale |
34.99 |
2,139 |
74,844 |
0 |
| CHICKO RHONDA M. | Chief Financial Officer |
Aug 14 '26 |
Option Exercise |
2.35 |
25,000 |
58,875 |
25,018 |
| Graul Regina Margaret | See Remarks |
Aug 14 '26 |
Option Exercise |
3.30 |
55,849 |
184,302 |
156,152 |
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):